Featured Content

Winston Wong, PharmD
President, W-Squared Group

New Guidelines For Cancer Doctors Aim To Make Sense Of Gene Tests

(Reuters) Aug 31, 2015 - The American Society of Clinical Oncology (ASCO) has issued guidelines on how cancer doctors should approach the use of new genetic tests that screen for multiple cancer genes at the same time, including counseling patients about genes whose contribution to cancer is still poorly understood.

Commentary: The concern that payers have is that there is no disagreement on those genes that have already shown clinical utility....

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Amgen Cannot Stop Imminent Sale Of Neupogen Copycat: U.S. Appeals Court

(Reuters) Sept 2, 2015 - A U.S. appeals court has cleared the way for Novartis AG to launch the first biosimilar drug in the United States as it declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen.
read article »

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients

(MarketWatch) Sept 2, 2015 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo for the treatment of previously treated patients with non-squamous (NSQ) non-small cell lung cancer (NSCLC).
read article »

FDA Approves New Drug Treatment For Nausea And Vomiting From Chemotherapy

(FDA.gov) Sept 2, 2015 - The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis).
read press release »

Novartis Receives EU Approval For New Revolade® Use As First-In-Class Therapy For Patients With Severe Aplastic Anemia

(NASDAQ) Sept 2, 2015 - Novartis announced today that the European Commission has approved Revolade® (eltrombopag) for the treatment of adults with severe aplastic anemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplant.
read article »


View ALL News »

News Story Commentary By Academic and Community Oncologists

New Guidelines For Cancer Doctors Aim To Make Sense Of Gene Tests (Reuters)

The concern that payers have is that there is no disagreement on those genes that have already shown clinical utility....posted by: Winston Wong, PharmD

Op-Ed: Cancer Cuts Are Too Deep (Baltimore Sun)

So I'm not "Waters" but welcome to my world...... I agree with my radiation colleagues but this is the same...posted by: Thomas, Marsland, MD

The FDA Is Basically Approving Everything. Here's The Data To Prove It (Forbes)

Maybe we should ask: Should the FDA change the way they look at drugs to approved them? Adopting a NICE type...posted by: Winston, Wong, PharmD

Blood Test Could Predict Breast Cancer's Return (Discovery News/AFP)

There are many emerging uses for technology that is able to detect and sequence DNA in the blood, including the...posted by: Debu Tripathy, MD

Side Effects May Lead Breast Cancer Patients To Skip Drugs (FoxNews.com/Reuters)

This is a real problem and concern. Hopefully payers will take note and start using the prognostic and predictive...posted by: Winston Wong, PharmD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.

OBR Job Board

Ipsen has 1 new job posted.

Dava Oncology has 1 new job posted.

Bayer has 7 jobs posted.

Seattle Genetics has 3 jobs posted.

Check out the OBR Job Board here.

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
ATRA +10.58%
IMDZ +10.52%
TKAI +10.04%
ARIA -17.03%
SPPI -5.70%
APRI -5.06%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: September 2, 2015
Company: Tesaro
Product: Varubi™ (rolapitant)

Date: October 2, 2015
Company: Merck
Product: Keytruda® (pembrolizumab)

Date: October 23, 2015
Company: Spectrum Pharmaceuticals
Product: Evomela™ (melphalan hydrochloride) for injection

See All OBR Radar items»